High intra-cardiac synthesis of FGF23 has been shown in patients with CKD and LVH (Leifheit-Nestler et al., 2016) as well as in animal models of experimental uremia (Leifheit-Nestler et al., 2017), myocardial infarction (Andrukhova et al., 2015; Schumacher et al., 2019) and after pulmonary artery banding (Kuga et al., 2020). Here, FGF23 is linked to chronic kidney disease.